Menopause and Menopausal Hormone Therapy in Women: Cardiovascular Benefits and Risks

Anna Svatikova, Sharonne N. Hayes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The last decade has brought many challenges and uncertainties regarding the use of menopausal hormone therapy in women. Two early key studies, the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women's Health Initiative (WHI) failed to prove beneficial effects of exogenous estrogen, and estrogen combined with progestin, in cardiovascular prevention. More recent studies, however, introduced the concept of a possible "window-of-opportunity" for hormonal therapy, in which menopausal hormone therapy is used early after the onset of menopause, and may lead to more favorable, cardio-protective outcomes. Despite the increasing wealth of clinical data, menopausal hormone therapy is not currently recommended for primary or secondary prevention of coronary heart disease in women. Further research is needed to understand the risk-benefit balance of menopausal hormone therapy.

Original languageEnglish (US)
JournalRevista Colombiana de Cardiologia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Menopause
Hormones
Progestins
Estrogens
Therapeutics
Estrogen Replacement Therapy
Women's Health
Primary Prevention
Secondary Prevention
Uncertainty
Coronary Disease
Research

Keywords

  • Cardiovascular prevention
  • Menopausal hormone therapy
  • Menopause
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Menopause and Menopausal Hormone Therapy in Women : Cardiovascular Benefits and Risks. / Svatikova, Anna; Hayes, Sharonne N.

In: Revista Colombiana de Cardiologia, 01.01.2018.

Research output: Contribution to journalArticle

@article{07858d3eac784853aec86728a79f9753,
title = "Menopause and Menopausal Hormone Therapy in Women: Cardiovascular Benefits and Risks",
abstract = "The last decade has brought many challenges and uncertainties regarding the use of menopausal hormone therapy in women. Two early key studies, the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women's Health Initiative (WHI) failed to prove beneficial effects of exogenous estrogen, and estrogen combined with progestin, in cardiovascular prevention. More recent studies, however, introduced the concept of a possible {"}window-of-opportunity{"} for hormonal therapy, in which menopausal hormone therapy is used early after the onset of menopause, and may lead to more favorable, cardio-protective outcomes. Despite the increasing wealth of clinical data, menopausal hormone therapy is not currently recommended for primary or secondary prevention of coronary heart disease in women. Further research is needed to understand the risk-benefit balance of menopausal hormone therapy.",
keywords = "Cardiovascular prevention, Menopausal hormone therapy, Menopause, Women",
author = "Anna Svatikova and Hayes, {Sharonne N.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.rccar.2017.12.004",
language = "English (US)",
journal = "Revista Colombiana de Cardiologia",
issn = "0120-5633",
publisher = "Sociedad Colombiana de Cardiologia y Cirugia Cardiovascular",

}

TY - JOUR

T1 - Menopause and Menopausal Hormone Therapy in Women

T2 - Cardiovascular Benefits and Risks

AU - Svatikova, Anna

AU - Hayes, Sharonne N.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The last decade has brought many challenges and uncertainties regarding the use of menopausal hormone therapy in women. Two early key studies, the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women's Health Initiative (WHI) failed to prove beneficial effects of exogenous estrogen, and estrogen combined with progestin, in cardiovascular prevention. More recent studies, however, introduced the concept of a possible "window-of-opportunity" for hormonal therapy, in which menopausal hormone therapy is used early after the onset of menopause, and may lead to more favorable, cardio-protective outcomes. Despite the increasing wealth of clinical data, menopausal hormone therapy is not currently recommended for primary or secondary prevention of coronary heart disease in women. Further research is needed to understand the risk-benefit balance of menopausal hormone therapy.

AB - The last decade has brought many challenges and uncertainties regarding the use of menopausal hormone therapy in women. Two early key studies, the Heart and Estrogen/Progestin Replacement Study (HERS) and the Women's Health Initiative (WHI) failed to prove beneficial effects of exogenous estrogen, and estrogen combined with progestin, in cardiovascular prevention. More recent studies, however, introduced the concept of a possible "window-of-opportunity" for hormonal therapy, in which menopausal hormone therapy is used early after the onset of menopause, and may lead to more favorable, cardio-protective outcomes. Despite the increasing wealth of clinical data, menopausal hormone therapy is not currently recommended for primary or secondary prevention of coronary heart disease in women. Further research is needed to understand the risk-benefit balance of menopausal hormone therapy.

KW - Cardiovascular prevention

KW - Menopausal hormone therapy

KW - Menopause

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85040120426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040120426&partnerID=8YFLogxK

U2 - 10.1016/j.rccar.2017.12.004

DO - 10.1016/j.rccar.2017.12.004

M3 - Article

AN - SCOPUS:85040120426

JO - Revista Colombiana de Cardiologia

JF - Revista Colombiana de Cardiologia

SN - 0120-5633

ER -